GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Bone Metastasis overview

Bone metastasis occurs when cancer cells spread from their original site to the bones, leading to secondary tumors. It is most commonly associated with cancers of the breast, lung, prostate, and kidney. Bone metastases can cause severe pain, fractures, and other complications, significantly impacting a patient’s quality of life. Treatment aims to manage symptoms, slow the progression of the disease, and improve overall survival. Therapeutic approaches may include radiation therapy, chemotherapy, hormone therapy, bisphosphonates, or targeted therapies tailored to the specific type of cancer. Early detection and a multidisciplinary treatment approach are crucial in effectively managing bone metastasis and enhancing patient outcomes.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

G lobalDat a, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.